期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

携带hTERT I540-PTD表达框重组复制缺陷型腺病毒的构建与鉴定

Construction and identification of recombinant replication-defective adenoviruses harbouring expression cassettes of I540-PTD and I540-PTD4
原文传递
导出
摘要 目的:构建携带人端粒酶逆转录酶亚基(hTERT)I540-PTD,I540-PTD4融合基因表达框的重组复制缺陷型腺病毒.方法:将pDC315-I540-PTD,pDC315-I540-PTD4与腺病毒基因组质粒pBHGloxdeltaE13Cre共转染HEK293细胞,出现典型的细胞病变反应后收获细胞,反复冻融法制备病毒粗提液,经扩增和纯化获得重组复制缺陷型腺病毒Ad-I540-PTD和Ad-I540-PTD4.使用终点稀释实验和空斑形成实验测定纯化后病毒滴度.采用聚合酶链式反应(PCR)对Ad-I540-PTD,Ad-I540-PTD4进行鉴定.使用病毒感染人骨肉瘤U2OS细胞后,进行免疫组化定性并观察I540-PTD,I540-PTD4的表达情况.结果:共转染10d后,HEK293细胞出现典型的细胞病变反应.经扩增、纯化后,终点稀释法和孔板形成法测定Ad-I540-PTD滴度分别为(8.9×1012),(6.3×1012)pfu/L;Ad-I540-PTD4滴度分别为(5.8×1012),(5.4×1012)pfu/L.以纯化的病毒为模板,使用自行设计的鉴定引物进行PCR均获得167bp目标片段.抗组胺酸标签抗体对病毒感染后的U2OS细胞免疫组化分析发现Ad-I540-PTD,Ad-I540-PTD4转染的U2OS细胞均呈强染,表明Ad-I540-PTD,Ad-I540-PTD4中携带的I540-PTD,I540-PTD4真核表达读框可在人类细胞内高效表达.结论:成功构建可高效表达I540-PTD,hTERTI540-PTD4的重组复制缺陷型重组腺病毒Ad-I540-PTD,Ad-I540-PTD4,为其作为基因疫苗诱发针对hTERT I540表位的抗瘤免疫奠定了基础. AIM： To construct the recombinant replicationdefective adenoviruses harbouring the expression cassettes of 1540- PTD and I540-PTD4 fusion genes. METHODS： Recombinant adenovirus was constructed by co-transfecting HEK293 cells with pDC315-I540-PTD and pDC315-I540-PTD4 with genomic plasmid pBHGloxdeltaE13Cre respectively. The infectious titers of Ad-I540-PTD and Ad-I540-PTD4 were tittered by end-point dilution assay and plaque assay. After infected with the recombinant viruses, the expression of I540-PTD and I540-PTD4 fusion proteins was analyzed by immunohistochemical staining. RESULTS： Ten days after co-transfecting HEK293 cells with pDC315-I540-PTD and pDC315-I540-PTD4 with genomic plasmid pBHGloxdeltaE13Cre respectively, typical cytopathic effects were seen. The lysates containing recombinant replication-defective adenoviruses Ad-1540-PTD and Ad-I540-PTD4 were obtained by three consecutive free-thaw cycles after harvesting the HEK293 cells. The infectious titers of Ad-I540-PTD and Ad-I540-PTD4 were （ 8.9 × 1012）and （6.3 × 10^12 ） pfu/L, （5.8 × 1012 ） and （5.4 × 10^12 ） pfu/L determined respectively by end-point dilution assay and by plaque assay. Ad-I540-PTD and Ad-I540-PTD4 were confirmed by amplifying the 167 bp products by PCR with specific primers using recombinant adenoviruses DNA as templates. Immunohistochemical analysis using anti-His tag monoclonal antibody demonstrated that the U20S infected with Ad-I540-PTD and Ad-I540- PTD4 was both strongly positively stained. CONCLUSION： We have successfully designed and constructed the recombinant replica- tion-defective adenoviruses Ad-I540-PTD and Ad-I540-PTD4 harbouring I540-PTD and I540-PTD4 expression cassette respectively.
作者 郭晓彤 黎静 薛妍 宣敏 李立文
机构地区 广州军区广州总医院肿瘤科 第四军医大学西京医院肿瘤科 西北大学生命科学学院
出处 《第四军医大学学报》 北大核心 2009年第9期796-799,共4页 Journal of the Fourth Military Medical University
基金 国家自然科学基金(30600750) 陕西省自然科学基金[2006K09-G9(5)]
关键词 癌症疫苗 端粒酶逆转录酶 肿瘤 免疫疗法 cancer vaccines hTERT neoplasms immunotherapy
分类号 R730 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Vonderheide RH. Universal tumor antigens for cancer vaccination: Targeting telomerase for immunoprevention [ J ]. Discov Med, 2007, 7(39) : 103 -108.
  • 2Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines [ J ]. Expert Rev Vaccines, 2008, 7 (7) : 881 - 887.
  • 3Wenandy L, Sorensen RB, Sengelov L, et al. The immunogenicity of the hTERT540 -548 peptide in cancer[ J]. Clin Cancer Res, 2008, 14(1) : 4 -7.
  • 4郭晓彤,张积仁,李立文.蛋白转导功能域在肿瘤疫苗领域的应用前景[J].第四军医大学学报,2004,25(21):2014-2016. 被引量：2
  • 5郭晓彤,张积仁,刘文超,任军,李立文.构建携带hTERT I540-PTD融合基因表达框的穿梭质粒[J].第四军医大学学报,2005,26(6):505-508. 被引量：2
  • 6Nguyen B, Elmore LW , Holt SE. Telomerase as a target for cancer immunotherapy[ J]. Cancer Biol Ther, 2003, 2(2) : 131 - 136.
  • 7Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy[J]. Cytotherapy, 2002, 4(4): 317-327.
  • 8Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer irmnunotherapy [ J ]. Oncogene, 2002, 21 (4) : 674 - 679.
  • 9Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8^+ T lymphocytes[J]. Clin Cancer Res, 2004, 10(3): 828 -839.
  • 10Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2. 1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells[ J] . Proc Natl Acad Sci USA, 2002, 99(19): 12275 -12280.

二级参考文献35

  • 1郭晓彤,张积仁,李立文.蛋白转导功能域在肿瘤疫苗领域的应用前景[J].第四军医大学学报,2004,25(21):2014-2016. 被引量：2
  • 2[1]Moy P, Daikh Y, Pepinsky B, et al. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens[J]. Mol Biotechnol, 1996;6(2):105-113.
  • 3[2]Kim DT, Mitchell DJ, Brockstedt DG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide[J]. J Immunol, 1997;159(4):1666-1668.
  • 4[3]Lu J, Wettstein PJ, Higashimoto Y, et al. TAP-independent presentation of CTL epitopes by Trojan antigens[J]. J Immunol, 2001; 166(12): 7063-7071.
  • 5[4]Leifert JA, Lindencrona JA, Charo J, et al. Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine[J]. Hum Gene Ther, 2001; 12(15): 1881-1892.
  • 6[5]Leifert JA, Holler PD, Harkins S, et al. The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes[J]. Gene Ther, 2003; 10(25): 2067-2073.
  • 7[6]Wang HY, Fu T, Wang G, et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells[J]. J Clin Invest, 2002; 109(11): 1463-1470.
  • 8[7]Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma[J]. Eur J Immunol, 2003; 33(4): 850-860.
  • 9[8]Tanaka Y, Dowdy SF, Linehan DC, et al. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells[J]. J Immunol, 2003; 170(3): 1291-1298.
  • 10[9]Kumar P, Krishna VD, Sulochana P, et al. Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: Analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain[J]. J Gen Virol, 2004; 85(Pt 2): 471-482.

共引文献2

第四军医大学学报
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部